Advertisement

Pharmakokinetik und -dynamik von Famotidin bei Patienten mit terminaler Niereninsuffizienz

  • U. Gladziwa
  • U. Klotz
  • D. R. Krishna
  • H. Schmitt
  • W. M. Glöckner
  • H. Mann
Conference paper

Zusammenfassung

Bei Niereninsuffizienz besteht eine erhöhte Inzidenz für das Auftreten peptischer Ulzera und gastrointestinaler Blutungen, die z T.auf eine Magensäurehypersekretion, z T.auf eine Hyper- gastrinämie zurückgeführt werden (Goldstein et al. 1967; Ritz et al. 1971; Venkateswaran et al. 1972; Shepherd et al. 1973; Milito et al. 1983, 1985).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Brodde OE & Daul A (1984). Alpha- and beta-adrenoceptor changes in patients on maintenance hemodialysis. Contrib. Nephrol., 41, 99–107.PubMedGoogle Scholar
  2. 2.
    Daul AE, Khalifa AM, Graven N & Brodde OE (1984). Impaired regulation of ß-adrenoceptors in patients on maintenance haemodialysis. Proc. Proc Eur Dial Transplant Assoc, 21, 178–183.Google Scholar
  3. 3.
    Garg DC, Weidler DJ & Eshelman FN (1983). Ranitidine bioavailability and kinetics in normal male subjects. Clin. Pharmacol. Ther., 33, 445–452.PubMedCrossRefGoogle Scholar
  4. 4.
    Goldstein H, Murphy D, Sokol A & Rubini ME (1967). Gastric acid secretion in patients undergoing chronic dialysis. Arch. Intern. Med.,. 120, 645–653.PubMedCrossRefGoogle Scholar
  5. 5.
    Halstenson CE, Abraham PA, Opsahl JA, Keane WF, Kovarik JM, Chremos AN & Matzke GR (1986). Disposition of famotidine (F) in renal insufficiency. Clin. Pharmacol. Ther., 39, 197.Google Scholar
  6. 6.
    Jones RH, Lewin MR & Parsons V (1979). Therapeutic effect of Cimetidine in patients undergoing haemodialysis. Brit. Med. J., 1, 650–652.PubMedCrossRefGoogle Scholar
  7. 7.
    Knoben JE & Anderson PO (1983). In: Hand Book of Clinical Drug Data in 5th Edn, pp 36. Illinois. Drug intelligence Publications.Google Scholar
  8. 8.
    Kroemer H & Klotz U (1987). Pharmacokinetics of famotidine in man. Int. J. Clin. Pharmacol. Ther. Toxicol. 25, 458–463.Google Scholar
  9. 9.
    Mann JFE, Hausen M, Jacobs KH, Kutter A, Nagel W, Rascher W, Schick M, Sudhoff R & Ritz E (1984). Adrenergic responsiveness in experimental uremia. Contrib. Nephrol., 41, 108–112.PubMedGoogle Scholar
  10. 10.
    Milito G, Taccone-Gallucci M, Brancaleone C, Nardi F, Fillingeri V, Cesca D & Casciani CU (1983). Assessment of the upper gastrointestinal tract hemodialysis patients awaiting renal transplantation. Am J Gastroenterol. 78, 328–331.PubMedGoogle Scholar
  11. 11.
    Milito G, Taccone-Gallucci M, Brancaleone C, Nardi F, Cesca D, Boffo V & Casciani CU (1985). The gastrointestinal tract in uremic patients on long-term hemodialysis. Kidney Int., 28, suppl. 17, S - 157 - 160Google Scholar
  12. 12.
    Peck CC & Barrett BB (1979). Nonlinear Least-Squares Regression Programs for micro-computers. J Pharmacokinet Biopharm., 5, 537 - 541CrossRefGoogle Scholar
  13. 13.
    Ritz E, Krempien B, Wanke M, Ziegler M, Wesch G & Torner U (1971). Klinische und experimentelle Untersuchungen zur urämischen Gastritis. Verh. Dtsch. Ges. Inn. Med., 77, 220 - 224PubMedGoogle Scholar
  14. 14.
    Schäfer U, Stiller S & Mann H (1986). Measurement of solute balance during dialysis therapy, Life support Systems - Abstracts XIII. Annual Meeting Europ. Soc. Artif. Organs, Avigon, pp 237 - 239Google Scholar
  15. 15.
    Shepherd, AMM, Stewart WK & Wormsley KG (1973). Peptic ulceration in chronic renal failure. Lancet., 1, 1357 - 1359PubMedCrossRefGoogle Scholar
  16. 16.
    Sica DA, Comstock T, Harford A & Eshelman F (1987). Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis. Eur. J. Clin. Pharmacol., 32, 587 - 591PubMedCrossRefGoogle Scholar
  17. 17.
    Smith JL, Gamal MA, Chremos AN & Graham DY (1985). Famotidine, a new H2-receptor antagonist: effect on parietal, nonparietal and pepsin secretion in man. Dig Dis Sei, 30, 308 - 312CrossRefGoogle Scholar
  18. 18.
    Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Saburo N, Shioki Y, Kawabata M, Hashimoto N & Hattori N (1983). Pharmacokinetics of famotidine in patients with renal insufficiency. Med Consultation, New Remedies., 20, 2061 - 2068Google Scholar
  19. 19.
    Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N & Hattori N (1985). Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function. Eur. J. Clin. Pharmacol. 28, 327 - 331PubMedCrossRefGoogle Scholar
  20. 20.
    Takabatake T, Ohta H, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, Satoh S, Sasaki T, Yamada Y, Ohta K & Hattori N (1986). Pharmacokinetics and dosage requirements of famotidine: a new H2-receptor antagonist, in renal failure. Dig Dis Sei 31, (Suppl), 274 S.Google Scholar
  21. 21.
    Venkateswaran PS, Jeffers A & Hocken AG (1972). Gastric acid secretion in chronic renal failure. Brit. Med. J., 4, 22 - 23CrossRefGoogle Scholar
  22. 22.
    Wagner JG (1975). Linear compartment models. In Fundamentals of Clinical Pharmacokinetics, pp 57 - 128, Illinois, Drug Int. PubGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • U. Gladziwa
  • U. Klotz
  • D. R. Krishna
  • H. Schmitt
  • W. M. Glöckner
  • H. Mann

There are no affiliations available

Personalised recommendations